Clinical validation study with PrismTcell use achieved approximately 2-fold higher ACR50 response rate to abatacept. FOR IMMEDIATE RELEASE Durham, NC.–(BUSINESS WIRE)–[Month Day], 2026–Scipher Medicine (Scipher), a leader in immunology precision...
Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the...
FOR IMMEDIATE RELEASE Every patient deserves a treatment they know will work for them.” ~ Reg Seeto, CEO, Scipher Medicine BURLINGTON, MA, UNITED STATES /EINPresswire.com/ — Scipher Medicine, a leader in precision medicine for autoimmune diseases, today...
FOR IMMEDIATE RELEASE Scipher Medicine and Senelix Announce Strategic Collaboration to Advance SL300 Development Baltimore, MD, March 10th, 2026 — Scipher Medicine and Senelix today announced a strategic collaboration to incorporate Scipher’s AI network platform to...
Drug discovery and development remains one of the most challenging and resource-intensive processes in modern medicine. With development timelines spanning 10-15 years and costs exceeding $1-3 billion per approved drug1, the need for more efficient target...
BURLINGTON, Mass.–(BUSINESS WIRE)–Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, today announced a strategic collaboration with Maxymune Therapeutics, a biotechnology company focused on research and development of novel...
WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, a leader in precision immunology, today announced the public launch of ClinicalTrialRank.com, an innovative artificial intelligence (AI) platform engineered to predict clinical trial failure with...
NEW YORK & WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, a leader in precision immunology, and Savant Bio, a Roivant-backed health data infrastructure company, today announced an expanded strategic partnership to build the world’s most advanced...
Novel “RA Response Calculator” Uses AI and Real Patient Data to Help Doctors Better Tailor Treatment Plans WALTHAM, MA – June 18, 2025 – At the European Congress of Rheumatology (EULAR) 2025, Scipher Medicine, the company behind the groundbreaking PrismRA® test,...
WALTHAM, Massachusetts – June 16, 2025 Scipher Medicine, a leading precision immunology company, today announced a strategic alliance with Grupo Amarey, a leading company in the representation and distribution of technologies, solutions, and services for the...
Partnership integrates Scipher’s PrismRA to deliver insights into therapy response segmentation WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, a precision immunology company dedicated to transforming patient care through data-driven insights, today...
Collaboration combines Scipher’s unique RNAseq data, part of the largest non-oncology clinico-transcriptomic data lake and biobank, with InnoSIGN’s proprietary Comprehensive Pathway Analysis (CPA) platform to enhance the understanding of complex...
The partnership integrates Kythera’s enriched high-fidelity multi-source EHR and claims data assets with real-world clinical and genomic data from Scipher’s PrismRA® Test, revealing new insights for precision medicine advancements. Waltham, MA-April 15, 2025 – Scipher...
Waltham, MA – Jan. 13, 2025 – Scipher Medicine, a leader in precision medicine for autoimmune diseases, and Roivant, a global biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that...
The partnership integrates transcriptome genomic data from Scipher’s PrismRA Test into OMNY’s EMR network, unlocking deeper patient insights for precision medicine advancements. Atlanta, Georgia – Jan. 9, 2025 – OMNY Health, the leading healthcare...
